We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

INOVA DIAGNOSTICS: WERFEN

Inova Diagnostics: Werfen manufactures in vitro diagnostics systems and reagents for autoimmune diseases for use in c... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Aug 2021 - 26 Aug 2021
Virtual Venue

Inova Diagnostics Receives FDA 510(k) Clearance for Digital Multi-Analyte System Aptiva

By LabMedica International staff writers
Posted on 30 Jun 2021
Print article
Image: Aptiva utilizes a particle-based multi-analyte technology (PMAT) (Photo courtesy of Inova Diagnostics)
Image: Aptiva utilizes a particle-based multi-analyte technology (PMAT) (Photo courtesy of Inova Diagnostics)
Inova Diagnostics (San Diego, CA, USA) has received FDA 510(k) clearance for its Aptiva System, a fully automated digital multi-analyte system that represents the next generation of high-throughput processors for the clinical laboratory.

The company has also been granted FDA 510(k) clearance for its Aptiva Celiac Disease IgA assay. Aptiva addresses many health economic shortcomings in the autoimmune laboratory. Existing systems provide a limited number of analytes that do not reduce the seronegative gap found in many disease states. Beyond the current Celiac assay, Aptiva will include seven additional autoimmune disease states and has over 60 analytes in various stages of advanced development. These additional analytes will help clinicians close the seronegative gap and improve diagnostic confidence.

Aptiva also delivers several economic benefits for the laboratory. The 150-sample rack capacity reduces the number of daily interventions and a 6.5-hour consumable walkaway time delivers new levels of workflow efficiencies. Aptiva uses a particle-based multi-analyte technology (PMAT) that processes multiple analytes simultaneously from a patient sample. PMAT enables Aptiva to deliver up to 720 results per hour using a 12-analyte test cartridge and allows the laboratory to complete its workflow in a single shift.

"Aptiva's broad disease and syndromic-based analyte portfolio is a breakthrough that fundamentally enhances the utility of diagnostic testing in the laboratory," said Michael Mahler, PhD., Vice President of Research and Development at Inova. "Aptiva will bring efficiency and reliability to the autoimmune laboratory and provide expanded information to clinicians for management of patients with autoimmune diseases."



Gold Supplier
Blood Glucose Laboratory Analyzer
Nova Primary
New
Magnetic Induction Thermocycler
CoDx Box
New
Portable Nucleic Acid Detection System
Mini8 Plus
New
Automated Pipetting Solution
PIPETMAX

Print article

Channels

Molecular Diagnostics

view channel
Image: The Lumipulse G β-amyloid 1-40 assay kit (Photo courtesy Fujirebio)

APOE Gene Influences Alzheimer's Symptoms, Biomarkers in Down Syndrome

Individuals with Down syndrome (DS) constitute a population at ultrahigh risk of developing Alzheimer disease (AD) because of trisomy of chromosome 21, which harbors the amyloid precursor protein (APP) gene.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.